Expertise

Trastuzumab

CCDRD AG was part of the clinical development of the originator product and participated in global phase III developments.

Morover, CCDRD AG has discussed and verified the clinical development strategy for biosimilar Trasutzumab with the European regulators.

Clinical work – 2 phase III trials and pharmacokinetic study

Efficacy study, multicentric

Breast cancer patients

Efficacy study, multicentric

Breast cancer patients

Pharmacokinetic study, monocentric

Healthy volunteers